Business
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for AQST-109 Epinephrine Sublingual Film at American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
WARREN, N.J., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing
About this update from Aquestive Therapeutics, Inc.
[{"type":"text","content":"WARREN, N.J., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today announced that four late breaking posters recapping the positive data from pharmacokinetic and pharmacodynamic studies of AQST-109 epinephrine sublingual film will be presented at the American Academy of Allergy, Asthma, and Immunology (AAAAI) annual meeting, which will be held from February 24-27 in San Antonio, Texas. “We are excited to share the positive results from our two completed AQST-109 pharmacokinetic and pharmacodynamic studies at the upcoming AAAAI Conference,” said Dan Barber, Aquestive’s President and Chief Executive Officer. “We look forward to engaging with leaders in the allergy community and providing insights into how our therapeutic candidate has the potential to provide an important advancement for the treatment of acute allergic reactions, if approved by the FDA.” “Collectively, the AQST-109 studies presented at the 2023 AAAAI add to an accumulating body of favorable evidence indicating that epinephrine delivered via sublingual film results in a rapid onset (i.e., Tmax) and an early, robust increase in other pharmacokinetic and pharmacodynamic parameters used to measure epinephrine efficacy,” stated John Oppenheimer, M.D., FAAAAI, Clinical Professor of Medicine at UMDNJ Rutgers, Pulmonary and Allergy Associated NJ. “The newly presented data also indicate that AQST-109 shows promise as a viable alternative for the management of anaphylaxis.” Poster Title: Impact of Food Exposure on the Pharmacokinetics of Epinephrine Sublingual FilmPoster Number: 7Presentation Time: Friday, February 24, 3:15-4:15 PM CTLead Author: John Oppenheimer, M.D., UMDNJ Rutgers University School of Medicine Poster Title: Pharmacokinetics and Pharmacodynamics of Epinephrine Sublingual Film Versus Intra-Muscular EpinephrinePoster Number: 12Presentation Time: Friday, February 24, 3:15-4:15 PM CTLead Author: David Golden, M.D., Medstar Franklin Square Hospital Poster Title: Pharmacokinetics of Epinephrine Sublingual Film Following Three Different Administration ProceduresPoster Number: 17Presentation Time: Friday, February 24, 3:15-4:15 PM CTLead Au...